To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate will use the money ...
Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...
KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- In alignment with U.S. Food and Drug Administration (FDA) requirements, Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing ...
KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Cingulate submitted its New Drug Application (NDA) for CTx-1301 to the FDA, targeting the ADHD market, with an NDA acceptance decision expected in late 2025. Operating expenses increased for the three ...
Hosted on MSN
What's going on with Cingulate stock today?
Cingulate Inc. CING shares were down during Friday’s premarket session but recovered later. The company’s recent financial report highlighted both operational advancements and ongoing challenges. The ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The private placement gives a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results